The firm is an early-stage venture capital fund established by a group of experienced medical device industry professionals in Asia. The firm typically invests approximately $700K–$3M in companies raising Angel, Pre-Series A, Series A, and Series B financings. The firm invests through a local-currency fund and therefore places a strong emphasis on international companies willing to establish a joint venture or meaningful operating presence in Asia. The firm’s partners leverage extensive medical device industry experience and local networks to help portfolio companies establish and grow their businesses in the Asian market. 

The firm primarily invests in medical devices and in vitro diagnostics, with particular expertise in cardiology, neuromodulation, diagnostic technologies, and medical imaging. The firm is also interested in R&D services and AI-enabled healthcare technologies, particularly technologies that use artificial intelligence to improve medical imaging, diagnostic accuracy, or clinical efficiency. While these areas represent the firm’s core expertise, the firm remains open to other differentiated medical technologies with strong development and commercialization potential. 

From a company and management team perspective, the firm strongly prefers opportunities with a clear Asia strategy and companies willing to collaborate closely with its investment partners. The firm can support international companies through local industry relationships, access to industrial and commercialization networks, and assistance in identifying potential non-dilutive funding opportunities. The firm seeks management teams that are receptive to strategic involvement and can leverage the firm’s operating experience and local resources to establish and expand their presence in Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an early-stage investment firm headquartered in Asia. The firm is actively seeking Seed through Series A opportunities and can invest up to approximately $3M over the lifecycle of a portfolio company. The firm evaluates opportunities across Asia, North America, and Europe and provides both financial and strategic support to emerging healthcare companies. 

The firm invests broadly across life sciences, including therapeutics, medical devices, diagnostics, and digital health. The firm is indication-agnostic and seeks cutting-edge technologies addressing a wide range of healthcare needs. As an early-stage investor, the firm is comfortable evaluating technologies at the preclinical or early development stage and maintains a flexible approach to different technologies and business models. 

From a company and management team perspective, the firm does not impose specific requirements. The firm can act as either a lead investor or co-investor, although the firm generally seeks a more active role and may prefer to lead when investing in very early-stage companies. Through relationships with healthcare organizations and strategic partners, the firm can also provide portfolio companies with operational, commercialization, and business development support. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Europe-based investment group invests through an evergreen structure. The firm typically deploys approximately $2–$20M per company and invests primarily in private companies with a focus on the Nordic region. Investments are generally structured as equity, although convertible loans may also be considered. The firm has a long track record of supporting healthcare companies through growth and public-market exits and typically seeks a small number of new investments each year. 

Within life sciences and healthcare, the firm focuses on therapeutics, medical technology, and healthtech. For therapeutics, the firm generally targets clinical-stage drug development companies and has particular interest in oncology and orphan or rare diseases. Within medical technology, the firm considers all device classes but generally favors companies approaching commercialization. In healthtech, the firm prioritizes solutions with demonstrated willingness to pay and sustainable business models, with a particular preference for B2B opportunities. 

From a company and management team perspective, the firm seeks private companies with strong development or commercial potential and takes an active approach following investment. The firm generally seeks board representation and works closely with portfolio companies as they progress through clinical development, commercialization, growth, and potential exit opportunities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

This investment firm is headquartered in Asia with offices in North America and focuses on early-stage investments in life sciences and healthcare. The firm typically participates in pre-Series A to Series B financing rounds, with initial investment sizes ranging from several hundred thousand dollars to several million dollars and the potential for follow-on investments. The firm seeks opportunities primarily in Europe, as well as North America and the United Kingdom. The firm is open to both leading and co-investing in financing rounds. 

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is open to evaluating digital health and AI-related companies but has limited investment activity in these areas to date. The firm takes an opportunistic approach across subsectors and indications, with areas of interest including immunology, immuno-oncology, central nervous system disorders, and kidney-related diseases. 

For therapeutics, the firm considers opportunities from Phase I and beyond, particularly companies with proof-of-concept data or clinical validation supporting their technologies. For medical devices and diagnostics, the firm generally seeks more mature companies with products or prototypes in development, along with clear regulatory approval strategies. 

The firm does not have specific requirements for management teams but prefers to work with founding teams that have prior entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

This single-family office represents private family interests in the United States. The firm is flexible in terms of investment size but generally looks to invest at least several hundred thousand dollars per round, depending on round size and anticipated capital requirements. The firm prefers Series A and later-stage companies, while pre-Series A opportunities are considered depending on technology maturity. Currently, the firm invests primarily in companies based in North America. 

The firm seeks breakthrough technologies with a strong social impact focus in the therapeutics, medical devices, and diagnostics sectors that address underserved medical needs or provide innovative and disruptive approaches to existing medical procedures and treatments. Areas of particular interest include optical and sound-based technologies, devices that reduce reliance on drug-based treatments, orthopedics, gene and nucleic acid-based therapies, immuno-oncology, and technologies addressing sensory loss. 

The firm reviews co-investment opportunities in private companies and, on an opportunistic basis, may consider investments in micro- and small-cap public companies as a direct investor. The firm seeks companies that have completed seed financing and have reached key intellectual property milestones, including allowance of claims by relevant patent authorities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.